Is insourcing NGS testing worth it?

Dartmouth-Hitchcock has experienced nearly 40% savings by bringing NGS testing in-house. A recent AMP study using non-small cell lung cancer as an example cites $2.7 million in anticipated savings.

In-house NGS testing is the foundation of any modern precision medicine program. It can have a profound effect on patient care. And, as these examples show, a strong business case can be made. 

How have Dartmouth-Hitchcock and other progressive institutions been so successful despite myriad challenges?

Join us for a webinar on May 31st at 12pm ET as Eric Loo, MD (Dartmouth-Hitchcock) and Rakesh Nagarajan, MD, PhD (PierianDx) explore answers to this question and more. 

In this webinar you will learn:

  • How recent precision medicine trends are driving strong market growth for clinical NGS and other complex molecular testing. 
  • How to make a strong business case for in-house NGS testing.
  • Challenges your institution is likely to face by insourcing.
  • Blueprints for overcoming these challenges, including reimbursement.